Smart combo attack: lung cancer trial matches drugs to tumor type
NCT ID NCT07172412
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 30 times
Summary
This study tests different drug combinations for people with extensive-stage small cell lung cancer who have not had prior treatment. Participants are assigned to a treatment arm based on specific markers in their tumor. The goal is to see if matching the drug to the tumor's biology improves outcomes. About 165 people will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE STAGE LUNG SMALL CELL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China 300060
Tianjin, Tianjin Municipality, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.